Syntaxin, Fibrocell name new CEOs; NIH outlines $32B budget

 @FierceBiotech:  Reuters: FDA to review Teva biosimilar of Amgen's Neupogen. Article | Follow @FierceBiotech

 @JohnCFierce: It didn't take long for the Acorda buyout talk to get started this morning. Follow John on Twitter

> Syntaxin has named Melanie Lee, PhD, CBE, FMedSci, DSc as the company's chief executive officer. Release

> Fibrocell Science, based in Exton, PA, has named David Pernock as its new CEO. Release

> Orexo AB says that its partner Kyowa Hakko Kirin has forged a joint distribution agreement for the cancer pain drug KW-2246 (Orexo's sublingual fentanyl product) with the pharmaceutical company Hisamitsu Pharmaceutical. Release

> Norway's Algeta ASA treated the first patient in a Phase II clinical study with Alpharadin for bone metastases resulting from endocrine-refractory breast cancer. Release

Pharma News

  @FiercePharma: Pharmalot: Cephalon Discloses Payments to Doctors. Article | Follow @FiercePharma

> One of the more interesting parts of Eli Lilly's Q4 earnings report was the section on Cialis, the ED drug. Lilly has doubled its price since its launch, yet that hasn't dampened demand. Story

> Kaiser trial supports Avastin eye use. Report

> The persistent job cuts in Big Pharma have some people looking for the bright side. Yes, thousands of employees are set to lose their paychecks. But that doesn't mean the sky is falling. Does it? Item

> How does pharma fare under President Obama's proposed budget? The short answer is so-so. Story

Biotech Research News

> Israel's Compugen saw its stock price shoot up 17 percent this morning on the news that it has discovered and completed early validation work on a promising protein that could prove an effective therapy for autoimmune diseases. Report

> Swiss drugmaker Roche has begun a Phase II study of a candidate to treat Fragile X syndrome, a condition that is the most common cause of autism yet identified, the FRAXA Research Foundation announced this week. Story

> In experiments published recently in Proceedings of the National Academy of Sciences and Brain Behavior and Immunity, researchers showed that dendritic cells native to the brain can muster the immune system's soldier T cells when confronted by certain threats. Item

Pharma Manufacturing News

> Drugs finished second--behind food and feed, but ahead of new cigarette and tobacco controls--in funding requests in the FDA's 2011 budget request. Story

> GMP consultants working for Caraco have put the finishing touches on a work plan that will let the drugmaker resume manufacturing at its Michigan facilities. The company now awaits FDA approval of the plan, in accordance with its consent decree. Story

> California, Florida, Texas, Georgia, Illinois and New Jersey are the top states for number of cargo thefts. Report

And Finally... The NIH is slated for a modest 3.2 percent budget hike for the next fiscal year in President Obama's newly proposed budget. But even with an extra billion dollars, the NIH will have $4 billion less to spend than it did this year after handing out a raft of research grants with money provided by the stimulus bill. FBR

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.